Hepatitis C virus genotype 5 variability in treatment naïve patients in South Africa
Introduction. Hepatitis C virus (HCV) genotype 5 was originally identified in South Africa, where it represents 35-60% of all HCV infections. There are limited data on resistance associated variants (RAVs) in South Africa. Thus, we investigated variability within the NS3/NS4A, NS5A, and NS5B gene...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-05-01
|
| Series: | Intervirology |
| Online Access: | https://beta.karger.com/Article/FullText/528178 |
| _version_ | 1797808842577281024 |
|---|---|
| author | Tshegofatso K. Maunye Maemu P. Gededzha Jason T. Blackard Johnny N. Rakgole Selokela G. Selabe |
| author_facet | Tshegofatso K. Maunye Maemu P. Gededzha Jason T. Blackard Johnny N. Rakgole Selokela G. Selabe |
| author_sort | Tshegofatso K. Maunye |
| collection | DOAJ |
| description | Introduction. Hepatitis C virus (HCV) genotype 5 was originally identified in South Africa, where it represents 35-60% of all HCV infections. There are limited data on resistance associated variants (RAVs) in South Africa. Thus, we investigated variability within the NS3/NS4A, NS5A, and NS5B genes of treatment-naïve patients individuals with HCV genotype 5 infection at the Dr George Mukhari Academic Hospital (DGMAH) in Pretoria, South Africa.
Methods. Nested PCR was performed to amplify the NS3/4A, NS5A and NS5B genes. RAVs were evaluated using the Geno2pheno tool.
Results. In the NS3/4A gene, F56S and T122A were detected in one sample each. The D168E mutation was detected in 7 samples. Within the NS5A gene, the T62M mutation was detected in 2 individuals. In the NS5B gene, 8 of 12 individuals (67%) had the A421V mutation, while all 12 individuals (100%) had the S486A mutation.
Discussion. RAVs were detected frequently among treatment-naïve individuals with HCV genotype 5 infection in South Africa. Thus, resistance testing may be prudent when initiating treatment of patients with genotype 5 infection. Additional population-based studies are needed to understand the prevalence of these RAVs during HCV genotype 5 infection. |
| first_indexed | 2024-03-13T06:43:41Z |
| format | Article |
| id | doaj.art-c7c4bc17c8df4cd3adf74f42ae297583 |
| institution | Directory Open Access Journal |
| issn | 0300-5526 1423-0100 |
| language | English |
| last_indexed | 2024-03-13T06:43:41Z |
| publishDate | 2023-05-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Intervirology |
| spelling | doaj.art-c7c4bc17c8df4cd3adf74f42ae2975832023-06-08T12:42:06ZengKarger PublishersIntervirology0300-55261423-01002023-05-011110.1159/000528178528178Hepatitis C virus genotype 5 variability in treatment naïve patients in South AfricaTshegofatso K. MaunyeMaemu P. Gededzhahttps://orcid.org/0000-0003-0686-1293Jason T. BlackardJohnny N. RakgoleSelokela G. Selabehttps://orcid.org/0000-0001-5101-5198Introduction. Hepatitis C virus (HCV) genotype 5 was originally identified in South Africa, where it represents 35-60% of all HCV infections. There are limited data on resistance associated variants (RAVs) in South Africa. Thus, we investigated variability within the NS3/NS4A, NS5A, and NS5B genes of treatment-naïve patients individuals with HCV genotype 5 infection at the Dr George Mukhari Academic Hospital (DGMAH) in Pretoria, South Africa. Methods. Nested PCR was performed to amplify the NS3/4A, NS5A and NS5B genes. RAVs were evaluated using the Geno2pheno tool. Results. In the NS3/4A gene, F56S and T122A were detected in one sample each. The D168E mutation was detected in 7 samples. Within the NS5A gene, the T62M mutation was detected in 2 individuals. In the NS5B gene, 8 of 12 individuals (67%) had the A421V mutation, while all 12 individuals (100%) had the S486A mutation. Discussion. RAVs were detected frequently among treatment-naïve individuals with HCV genotype 5 infection in South Africa. Thus, resistance testing may be prudent when initiating treatment of patients with genotype 5 infection. Additional population-based studies are needed to understand the prevalence of these RAVs during HCV genotype 5 infection.https://beta.karger.com/Article/FullText/528178 |
| spellingShingle | Tshegofatso K. Maunye Maemu P. Gededzha Jason T. Blackard Johnny N. Rakgole Selokela G. Selabe Hepatitis C virus genotype 5 variability in treatment naïve patients in South Africa Intervirology |
| title | Hepatitis C virus genotype 5 variability in treatment naïve patients in South Africa |
| title_full | Hepatitis C virus genotype 5 variability in treatment naïve patients in South Africa |
| title_fullStr | Hepatitis C virus genotype 5 variability in treatment naïve patients in South Africa |
| title_full_unstemmed | Hepatitis C virus genotype 5 variability in treatment naïve patients in South Africa |
| title_short | Hepatitis C virus genotype 5 variability in treatment naïve patients in South Africa |
| title_sort | hepatitis c virus genotype 5 variability in treatment naive patients in south africa |
| url | https://beta.karger.com/Article/FullText/528178 |
| work_keys_str_mv | AT tshegofatsokmaunye hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica AT maemupgededzha hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica AT jasontblackard hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica AT johnnynrakgole hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica AT selokelagselabe hepatitiscvirusgenotype5variabilityintreatmentnaivepatientsinsouthafrica |